Epilepsy and Seizure Medication
  Novartis Pharma US

 





MONOTHERAPY is a realistic goal - See results from a study showing that more patients achieved seizure control with their first antiepileptic drug monotherapy than with their second  monotherapy. Go

Novartis Medicare Resource Center

Patient Assistance Program - visit www.pap.novartis.com

Adult Dosing

Adult Dosing

TRILEPTAL makes dosing easy for your adult patients with partial seizures

Convenient BID dosing
Can be taken with or without food
Linear pharmacokinetics with no autoinduction

Adult dosing: monotherapy or adjunctive therapy*

Dosing Chart

Man
Pediatric Dosing
Adult Dosing
Tablet to Oral Suspension Conversion
How Supplied


A lower starting dosage and slower titration may be considered for some patients as clinically indicated
When converting to TRILEPTAL monotherapy, concomitant antiepileptic drugs should be completely withdrawn over 3 to 6 weeks, while the maximum dosage of TRILEPTAL should be reached in about 2 to 4 weeks

* In patients with renal impairment (creatinine clearance <30 mL/min), TRILEPTAL should be initiated at one half the usual dosage and increased slowly.
When TRILEPTAL is used as add-on therapy at dosages >1200 mg/day, a decrease in the dose of phenytoin may be required.




E-mail this page  | Print this page




TRILEPTAL Home  |  Professionals Main Page  |  Efficacy
Safety and Tolerability  |  Dosing  |  Resource Center
Important Safety Information  |  Prescribing Information

Site Guide  |  Contact Us  |  Sitemap

Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement .
Copyright ©2008
Novartis Pharmaceuticals Corporation. All rights reserved.